NOXXON Pharma N.V. announced that the first patient was enrolled in an expansion arm of the GLORIA clinical trial of NOX-A12 in MGMT unmethylated brain cancer (glioblastoma, GBM). The patient has received their first week of treatment of NOX-A12 (600 mg/week) and the VEGF inhibitor bevacizumab combined with radiotherapy. The GLORIA Phase 1/2 clinical trial evaluates the safety and efficacy of NOX-A12 combined with radiotherapy. In three expansion arms, the synergistic benefit of NOX-A12 with other therapeutic settings will be evaluated: Arm A: NOX-A12 with radiotherapy in patients with complete tumor resection; Arm B: NOX-A12 with radiotherapy and bevacizumab in patients with incomplete tumor resection; Arm C: NOX-A12 with radiotherapy and anti-PD-1 in patients with incomplete tumor resection. Each expansion arm plans to evaluate 6 patients.